drugset / Trial / NCT00702299
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with cisplatin and paclitaxel and giving them in different ways may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of intraperitoneal pemetrexed when given together with intraperitoneal cisplatin and paclitaxel in treating patients with stage III ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.
Timeline
- Start
- 2007-09
- Primary completion
- 2012-01
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | Other |
| Subject | Pemetrexed | Small molecule | 60 mg/m2 | Other |
| Subject | Pemetrexed | Small molecule | 120 mg/m2 | Other |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Other |
| Subject | Pemetrexed | Small molecule | 750 mg/m2 | Other |
| Subject | Pemetrexed | Small molecule | 1000 mg/m2 | Other |